Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma
Protocol ID
REGO-EWING
Disease (Sub Disease)
Multimetastatic Ewing Sarcoma
Diagnosis Stage
Newly diagnosed
Location
QLD, VIC, WA
Sponsor
Australian & New Zealand Children's Haematology/Oncology Group
Collaborators
Gustave Roussy, Cancer Campus, Grand Paris
Links
Trial Status
Open
Sites
Perth Children's Hospital
Queensland Children's Hospital
Monash Children's Hospital
Queensland Children's Hospital
Monash Children's Hospital
Study Type
Treatment
Phase
Phase 1
Age Eligibility
2 Years to 50 Years
International registry ID's
NCT05830084
| Study Title | Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma |
|---|---|
| Protocol ID | REGO-EWING |
| Disease (Sub Disease) | Multimetastatic Ewing Sarcoma |
| Diagnosis Stage | Newly diagnosed |
| Location | QLD / VIC / WA |
| Sponsor | Australian & New Zealand Children's Haematology/Oncology Group |
| Collaborators | Gustave Roussy, Cancer Campus, Grand Paris |
| Links | https://clinicaltrials.gov/study/NCT05830084 |
| Trial Status | Open |
| Trial Open Date | 27/03/2023 |
| Sites | Perth Children's Hospital / Queensland Children's Hospital / Monash Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1 |
| Age Eligibility | 2 Years to 50 Years |
| International registry ID's | NCT05830084 |